Xin Litai Subsidiary Co., Ltd. Participates in Maxim and Cerebrovascular Interventional Medical Devices Co., Ltd.

Medical Network May 3th Lixin announced on the morning of the 3rd, in order to improve the company's strategic layout in the cardiovascular and cerebrovascular field, and strengthen international innovation research and development cooperation, the company's wholly-owned subsidiary Nuotai International Co., Ltd. plans to use its own funds 399.9998 Ten thousand US dollars, subscribed for 1,039,960 shares of the newly issued D round of preferred shares of Mercator MedSystems, Inc. After the completion of the subscription, Nuotai will hold a 5.07% stake in the target company and become the target company’s shareholder.

In addition, NuoTai shall be entitled to the preferential rights of the Target Company for an additional 1,039,960 Series D Preferred Shares on the same terms. If this portion of the Shares is to be acquired, NuoTai will invest a total of US$7.99996 million and 2,079,920 Target Companies, which will be the target. 9.08% shares of the company.

Mercator MedSystems, Inc. has marketed the Bullfrog® microneedle delivery system for atherosclerotic lower extremity disease In addition, Mercator MedSystems, Inc. has a number of interventional device projects under development on the Microneedle Delivery System. Cancer , hypertension , Breathing and other areas to expand, the market prospects are good.